A
71.97
1.58 (2.24%)
| Previous Close | 70.39 |
| Open | 70.92 |
| Volume | 321,517 |
| Avg. Volume (3M) | 733,793 |
| Market Cap | 4,917,007,360 |
| Price / Book | 8.98 |
| 52 Weeks Range | |
| Earnings Date | 10 Nov 2025 |
| Diluted EPS (TTM) | -3.61 |
| Total Debt/Equity (MRQ) | 1.75% |
| Current Ratio (MRQ) | 15.82 |
| Operating Cash Flow (TTM) | -188.02 M |
| Levered Free Cash Flow (TTM) | -120.81 M |
| Return on Assets (TTM) | -19.65% |
| Return on Equity (TTM) | -27.85% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Apogee Therapeutics, Inc. | Bullish | Bullish |
AIStockmoo Score
0.7
| Analyst Consensus | 1.5 |
| Insider Activity | -1.5 |
| Price Volatility | -3.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 4.0 |
| Average | 0.70 |
|
Apogee Therapeutics Inc is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology (I&I) indications with high unmet need. Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 7.62% |
| % Held by Institutions | 137.71% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 115.00 (BTIG, 59.79%) | Buy |
| Median | 105.00 (45.89%) | |
| Low | 70.00 (RBC Capital, -2.74%) | Buy |
| Average | 100.40 (39.50%) | |
| Total | 5 Buy | |
| Avg. Price @ Call | 58.77 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Deutsche Bank | 10 Dec 2025 | 103.00 (43.12%) | Buy | 76.06 |
| Craig-Hallum | 03 Nov 2025 | 109.00 (51.45%) | Buy | 54.35 |
| RBC Capital | 03 Nov 2025 | 70.00 (-2.74%) | Buy | 54.35 |
| 25 Sep 2025 | 60.00 (-16.63%) | Buy | 37.52 | |
| Mizuho | 21 Oct 2025 | 105.00 (45.89%) | Buy | 55.87 |
| BTIG | 09 Oct 2025 | 115.00 (59.79%) | Buy | 53.21 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| DAMBKOWSKI CARL | - | 75.50 | -10,900 | -822,950 |
| HENDERSON JANE | - | 75.50 | -1,500 | -113,250 |
| HENDERSON MICHAEL THOMAS | - | 75.50 | -40,000 | -3,020,000 |
| Aggregate Net Quantity | -52,400 | |||
| Aggregate Net Value ($) | -3,956,200 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 75.50 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| HENDERSON MICHAEL THOMAS | Officer | 04 Dec 2025 | Automatic sell (-) | 40,000 | 75.50 | 3,020,000 |
| HENDERSON JANE | Officer | 04 Dec 2025 | Automatic sell (-) | 1,500 | 75.50 | 113,250 |
| DAMBKOWSKI CARL | Officer | 04 Dec 2025 | Automatic sell (-) | 10,900 | 75.50 | 822,950 |
| Date | Type | Details |
|---|---|---|
| 10 Nov 2025 | Announcement | Apogee Therapeutics Provides Pipeline Progress and Reports Third Quarter 2025 Financial Results |
| 10 Nov 2025 | Announcement | Apogee Therapeutics Announces Positive Interim Phase 1 Results from Healthy Volunteer Trial of APG333, its Novel Half-Life Extended TSLP Antibody |
| 03 Nov 2025 | Announcement | Apogee Therapeutics to Participate in Upcoming Conferences |
| 10 Oct 2025 | Announcement | Apogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $345 Million |
| 08 Oct 2025 | Announcement | Apogee Therapeutics, Inc. Announces Proposed Underwritten Public Offering |
| 08 Oct 2025 | Announcement | Apogee Therapeutics, Inc. Announces Pricing of $300 Million Underwritten Public Offering |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |